tiprankstipranks
Advertisement
Advertisement

SBMFF Stock Latest News

Sino Biopharm Advances Kylo-11 With First U.S. Patient in Phase II Trial
Company AnnouncementsSino Biopharm Advances Kylo-11 With First U.S. Patient in Phase II Trial
3d ago
Sino Biopharm Wins Early Greater Bay Area Nod for Naldemedine in Opioid-Induced Constipation
PremiumCompany Announcements
Sino Biopharm Wins Early Greater Bay Area Nod for Naldemedine in Opioid-Induced Constipation
3d ago
Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205
PremiumCompany Announcements
Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205
4d ago
Sino Biopharmaceutical Completes Hygieia Acquisition With Performance-Linked Payout Structure
PremiumCompany Announcements
Sino Biopharmaceutical Completes Hygieia Acquisition With Performance-Linked Payout Structure
13d ago
Sino Biopharm Buys HK$27 Million in Shares for Award Scheme
PremiumCompany Announcements
Sino Biopharm Buys HK$27 Million in Shares for Award Scheme
16d ago
Sino Biopharm lifts profit on surging innovative drug sales in 2025
PremiumCompany AnnouncementsSino Biopharm lifts profit on surging innovative drug sales in 2025
17d ago
Sino Biopharm Proposes HKD 0.05 Final Dividend for 2025
Premium
Company Announcements
Sino Biopharm Proposes HKD 0.05 Final Dividend for 2025
17d ago
Sino Biopharmaceutical to Rebrand English Stock Short Name and Website
Premium
Company Announcements
Sino Biopharmaceutical to Rebrand English Stock Short Name and Website
17d ago
Sino Biopharmaceutical Wins MSCI ESG Rating Upgrade to AA on Green and Social Push
PremiumCompany Announcements
Sino Biopharmaceutical Wins MSCI ESG Rating Upgrade to AA on Green and Social Push
20d ago
Sino Biopharm Wins NMPA Nod for First-in-Class Osteoarthritis Drug Trial
PremiumCompany Announcements
Sino Biopharm Wins NMPA Nod for First-in-Class Osteoarthritis Drug Trial
26d ago
Sino Biopharmaceutical Sets Board Meeting to Approve 2025 Results and Consider Dividend
PremiumCompany Announcements
Sino Biopharmaceutical Sets Board Meeting to Approve 2025 Results and Consider Dividend
27d ago
Sino Biopharm Reports Breakthrough Phase III Success for IDH1 Inhibitor in Biliary Tract Cancer
PremiumCompany Announcements
Sino Biopharm Reports Breakthrough Phase III Success for IDH1 Inhibitor in Biliary Tract Cancer
1M ago
Sino Biopharm Wins NMPA Nod to Trial Pan-KRAS Cancer Drug TQB3205
PremiumCompany AnnouncementsSino Biopharm Wins NMPA Nod to Trial Pan-KRAS Cancer Drug TQB3205
1M ago
Sino Biopharm Grants Sanofi Global Rights to First-in-Class JAK/ROCK Drug Rovadicitinib
Premium
Company Announcements
Sino Biopharm Grants Sanofi Global Rights to First-in-Class JAK/ROCK Drug Rovadicitinib
1M ago
Sino Biopharm Wins China Approval for First-in-Class Myelofibrosis Drug
Premium
Company Announcements
Sino Biopharm Wins China Approval for First-in-Class Myelofibrosis Drug
1M ago
Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug
PremiumCompany Announcements
Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug
2M ago
Sino Biopharm Completes Phase III Enrollment for Next-Gen HER2-Low Breast Cancer Drug
PremiumCompany Announcements
Sino Biopharm Completes Phase III Enrollment for Next-Gen HER2-Low Breast Cancer Drug
2M ago
Sino Biopharm’s CLDN18.2 ADC Becomes First to Complete Phase III Enrollment
PremiumCompany Announcements
Sino Biopharm’s CLDN18.2 ADC Becomes First to Complete Phase III Enrollment
2M ago
Sino Biopharm’s Hepatitis B Drug TQA3605 Hits Key Goal in Phase II Trial
PremiumCompany Announcements
Sino Biopharm’s Hepatitis B Drug TQA3605 Hits Key Goal in Phase II Trial
3M ago
Sino Biopharm Buys siRNA Specialist Hygieia in RMB1.2 Billion Chronic Disease Push
PremiumCompany AnnouncementsSino Biopharm Buys siRNA Specialist Hygieia in RMB1.2 Billion Chronic Disease Push
3M ago
Sino Biopharm Appoints New Company Secretary and Authorised Representative
Premium
Company Announcements
Sino Biopharm Appoints New Company Secretary and Authorised Representative
3M ago
Sino Biopharm Advances First-in-Class ROCK2 Inhibitor TDI01 Into Global First Phase III IPF Trial
Premium
Company Announcements
Sino Biopharm Advances First-in-Class ROCK2 Inhibitor TDI01 Into Global First Phase III IPF Trial
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >